Iovance Biotherapeutics, Inc. (IOVA)
Grows patients' own immune cells to attack solid tumors like melanoma and lung cancer.
$4.68-0.05%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+74.4%
The outlook
IOVA is trading above its key moving averages and sits well into the upper half of its 52-week range. Analyst consensus leans strongly toward Buy, with an average price target implying roughly 88% upside from current levels. The stock's technical positioning and analyst sentiment both suggest optimism, though current price action remains subdued.
What’s behind the score
Analyst consensusBuy — 1.6 avg of 10 analysts
Price trendAbove its 50- & 200-day averages
52-week range75% of the way from its 52-week low to high
Price targetAvg target +88% vs current price
Analyst price target
~12-month · 10 analysts$8.80average target+88.2% vs now
Now $4.68
Low $4.00High $14.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.09B
52-wk high
$5.64
52-wk low
$1.76
50-day avg
$4.20
200-day avg
$3.25
Trailing P/E
—